Renhe Pharmacy Co Ltd Asset Resilience Ratio
Renhe Pharmacy Co Ltd asset resilience ratio. Renhe Pharmacy Co Ltd (000650) has an Asset Resilience Ratio of 37.54% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 000650 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Renhe Pharmacy Co Ltd (2009–2025)
Asset resilience ratio of Renhe Pharmacy Co Ltd from 2009 to 2025. This chart shows how Renhe Pharmacy Co Ltd's Asset Resilience Ratio has changed over time. Read Renhe Pharmacy Co Ltd (000650) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Renhe Pharmacy Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Renhe Pharmacy Co Ltd asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥2.98 Billion | 37.54% |
| Total Liquid Assets | CN¥2.98 Billion | 37.54% |
Asset Resilience Insights
- Very High Liquidity: Renhe Pharmacy Co Ltd maintains exceptional liquid asset reserves at 37.54% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Renhe Pharmacy Co Ltd Industry Peers by Asset Resilience Ratio
Compare Renhe Pharmacy Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
|
Orchid Pharma Limited
NSE:ORCHPHARMA |
Drug Manufacturers - Specialty & Generic | 4.03% |
Renhe Pharmacy Co Ltd Asset Resilience Ratio by Year (2009–2025)
Renhe Pharmacy Co Ltd asset resilience ratio by year from 2009 to 2025. The table below shows the annual Asset Resilience Ratio data for Renhe Pharmacy Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 14.13% | CN¥1.09 Billion ≈ $159.95 Million |
CN¥7.74 Billion ≈ $1.13 Billion |
+0.54pp |
| 2024-12-31 | 13.59% | CN¥1.02 Billion ≈ $148.83 Million |
CN¥7.48 Billion ≈ $1.09 Billion |
+1.24pp |
| 2023-12-31 | 12.36% | CN¥919.96 Million ≈ $134.62 Million |
CN¥7.44 Billion ≈ $1.09 Billion |
+6.89pp |
| 2022-12-31 | 5.46% | CN¥416.87 Million ≈ $61.00 Million |
CN¥7.63 Billion ≈ $1.12 Billion |
+0.89pp |
| 2021-12-31 | 4.57% | CN¥315.60 Million ≈ $46.18 Million |
CN¥6.91 Billion ≈ $1.01 Billion |
-2.74pp |
| 2020-12-31 | 7.31% | CN¥460.89 Million ≈ $67.44 Million |
CN¥6.31 Billion ≈ $922.63 Million |
-8.84pp |
| 2019-12-31 | 16.15% | CN¥805.14 Million ≈ $117.82 Million |
CN¥4.98 Billion ≈ $729.38 Million |
+15.98pp |
| 2018-12-31 | 0.17% | CN¥7.86 Million ≈ $1.15 Million |
CN¥4.62 Billion ≈ $675.56 Million |
-0.07pp |
| 2017-12-31 | 0.24% | CN¥9.99 Million ≈ $1.46 Million |
CN¥4.17 Billion ≈ $609.82 Million |
+0.01pp |
| 2016-12-31 | 0.23% | CN¥8.81 Million ≈ $1.29 Million |
CN¥3.86 Billion ≈ $565.56 Million |
-0.03pp |
| 2015-12-31 | 0.26% | CN¥8.21 Million ≈ $1.20 Million |
CN¥3.16 Billion ≈ $461.86 Million |
+0.00pp |
| 2014-12-31 | 0.26% | CN¥6.73 Million ≈ $985.27K |
CN¥2.60 Billion ≈ $380.04 Million |
+0.04pp |
| 2013-12-31 | 0.22% | CN¥5.22 Million ≈ $763.17K |
CN¥2.33 Billion ≈ $340.76 Million |
-0.04pp |
| 2012-12-31 | 0.26% | CN¥5.54 Million ≈ $810.28K |
CN¥2.09 Billion ≈ $306.54 Million |
-0.25pp |
| 2011-12-31 | 0.52% | CN¥8.29 Million ≈ $1.21 Million |
CN¥1.60 Billion ≈ $234.54 Million |
-0.11pp |
| 2010-12-31 | 0.63% | CN¥9.25 Million ≈ $1.35 Million |
CN¥1.48 Billion ≈ $216.30 Million |
-0.12pp |
| 2009-12-31 | 0.74% | CN¥7.88 Million ≈ $1.15 Million |
CN¥1.06 Billion ≈ $155.24 Million |
-- |
About Renhe Pharmacy Co Ltd
Renhe Pharmacy Co.,Ltd produces and sells pharmaceutical products. It offers Chinese and western medicines and raw materials; and health-related products, including oral solid preparations and liquid preparations, large-volume and small-volume injections, external lotions, liniments, suppositories, ointments, and other dosage forms of drugs and health-related products. The company was founded in … Read more